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Rab GTPases are well-recognized targets in human disease, although are
underexplored therapeutically. Elucidation of how mutant or dysregulated
Rab GTPases and accessory proteins contribute to organ speciﬁc and
systemic disease remains an area of intensive study and an essential
foundation for effective drug targeting. Mutation of Rab GTPases or
associated regulatory proteins causes numerous human genetic diseases.
Cancer, neurodegeneration and diabetes represent examples of acquired
human diseases resulting from the up- or downregulation or aberrant
function of Rab GTPases. The broad range of physiologic processes and
organ systems affected by altered Rab GTPase activity is based on pivotal
roles in responding to cell signaling and metabolic demand through the
coordinated regulation of membrane trafﬁcking. The Rab-regulated
processes of cargo sorting, cytoskeletal translocation of vesicles and
appropriate fusion with the target membranes control cell metabolism,
viability, growth and differentiation. In this review, we focus on Rab
GTPase roles in endocytosis to illustrate normal function and the
consequences of dysregulation resulting in human disease. Selected
examples are designed to illustrate how defects in Rab GTPase cascades
alter endocytic trafﬁcking that underlie neurologic, lipid storage, and
metabolic bone disorders as well as cancer. Perspectives on potential
therapeutic modulation of GTPase activity through small molecule
interventions are provided.
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The Ras superfamily of GTPases governs traf-
ﬁcking, cytoskeletal regulation and cell signal-
ing, through the interdigitated functions of Rab,
Arf/Arl, Rho, Ras and Ran subfamily members.
In this review we focus on the Rab GTPases
that function in endocytosis and recycling, phago-
cytosis, autophagy and pinocytosis (Fig. 1, left
side). As noted in Fig. 1, endocytic Rab GTPases
also play vital roles in lysosome biogenesis and
ciliogenesis reviewed in Refs. (1–3). We contrast
normal function to the consequences of Rab
GTPase or accessory protein dysfunction in genetic
or acquired diseases (Fig. 1, right side). Using
pathway speciﬁc examples we provide informa-
tion on the mechanistic underpinnings of normal
function and alterations that lead to disease. Muta-
tions in the Rab GTPases and accessory proteins
themselves, altered GTPase expression or activity
are relevant to neurologic and neurodegenerative
diseases, lipid storage disorders and cancer. The
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Genetic Diseases 
Endocytic Rab GTPases 
Normal cellular and molecular functions
Cancer
(e.g. Breast, 
Ovarian)
Neurologic
Diseases
(e.g. Charcot-Marie-
Tooth Disease Type 
2, Niemann-Pick 
Disease type C) 
Pigmentation,
Bleeding, Immune, 
Skeletal/Bone,
Kidney Retinal 
Diseases
(e.g. Griscelli 
Syndrome Type 2, 
Choroideremia,
Carpenter
syndrome, Bardet-
Biedl syndrome, 
arthrogryposis-renal-
cholestasis)
Alterations in disease 
Altered GTPase 
expression or activity 
Lysosome 
biogenesis and 
regulated
secretion
Metabolic
(e.g. obesity, 
diabetes)
Extracellular
cargo uptake; 
integration of 
signaling; vesicle 
trafficking, cargo 
sorting, cyto-
skeletal
translocation,
membrane fusion
Endocytosis
and  recycling 
Aberrant cell growth and differentiation 
Altered cell motility, adhesion, invasiveness 
Increased lipid storage 
Hypopigmentation, reduced coagulation, immune dysfunction 
Kidney failure 
Osteopetrosis, craniosynostosis, polydactyly 
 Retinal and/or neuronal degeneration 
Acquired Diseases 
Neuro-
degenerative
(e.g.
Alzheimer’s 
and
Huntington’s 
diseases)
Ciliogenesis and 
ciliary trafficking 
Degradation,
autophagy, 
phagocytosis,
pinocytosis
Lipid
homeostasis,
nutrient status, 
metabolite and 
receptor
degradation,
pathogen
clearance
Specialized granule 
formation and 
release for 
pigmentation,
immune, bone and 
blood clotting 
functions
Development,
differentiation 
and signaling 
Mutations in Rab GTPase or
altered activity of GTPase or effector 
Infectious
Coordinated Rab GTPase function 
on interconnected pathways 
Integrated GTPase cascades 
(Rho, Arf/Arl, Rab, Ran, Ras) 
Organ development and function 
Skeletal formation 
Normal cell differentiation and polarization 
Cell metabolism and homeostasis 
Immune function 
Coagulation
Fig. 1. Rab GTPases in normal cellular and molecular functions vs alterations in human disease. (Left panel) Normal functions of
endocytic Rab GTPases in (i) endocytosis and recycling, (ii) degradative pathways (including autophagic and phagocytic pathways),
(iii) lysosome biogenesis and regulated secretion, (iv) ciliogenesis and ciliary trafﬁcking. (Right panel) Disease-causing alterations
in Rab GTPase function may be acquired or genetic leading to loss of function, increased or decreased expression or activity.
pivotal roles of small GTPases in disease make
them attractive targets for therapeutic intervention
that have not yet been broadly explored. We also
illustrate the fundamental aspects for GTPase reg-
ulation that provide possible paradigms for small
molecule therapeutics.
Rab GTPase regulated endocytosis, recycling
and signaling
Among the over 70 mammalian Rab GTPases (4),
there are ∼20 Rab proteins with deﬁned functions
in endocytosis and related processes (Table 1).
Early endocytic and recycling routes are summa-
rized in Fig. 2 (green section). Receptor-mediated
endocytosis occurs via clathrin-coated vesicles
and is principally regulated by Rab5 and Rab21,
sharing common regulatory and effector pro-
teins (5, 6). Following internalization, sorting in
the early endosome segregates molecules for
return to the plasma membrane along fast (Rab4,
Rab14, Rab15) and slow (Rab11a, Rab15, Rab22a)
recycling routes (7–11). Epithelia have specialized
recycling circuits that utilize Rab17 and Rab25
in addition to the ubiquitous Rab4, Rab5 and
Rab11 GTPases (12). Early endosomes also regu-
late return to the Golgi via Rab6 and the retromer
complex, which may also interact with Rab7 (13,
14). From late endosomes, return to the Golgi is
regulated by Rab9, STX10 and Tip47 (15). Thus,
endosomes and associated Rab GTPases serve in
cargo sorting for plasma membrane and Golgi
recycling, as well as for degradation.
The early internalization and recycling circuits
are subject to up- or downregulation in response to
signaling and cellular demand. For example, epi-
dermal growth factor receptor (EGFR) signaling
through Ras increases the activity of Rin1 whose
guanine nucleotide exchange factor (GEF) activity
causes Rab5 association with signal-transducing
adaptor molecule 2 (STAM2) to increase EGFR
internalization and degradation (16). Rab11a acti-
vation on the other hand increases EGFR recy-
cling in response to EGF signaling and the
Rab5 GTPase activating protein (GAP), RN-TRE,
decreases EGFR endocytosis through Grb2 (17).
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Table 1. Rab GTPase functions, networks and disease associationsa,b
Rab Localization Rab function Pathological condition
Endocytosis and recycling
Rab4a Early endosomes and
recycling endosomes
Regulates sorting and endocytic
recycling to the plasma
membrane
Upregulated in rodent model
of diabetic
cardiomyopathy, human
systemic lupus
erythematosus,
Alzheimer’s disease and
Down’s syndrome;
inhibited in Niemann–Pick
disease; downregulated in
tumor cells
Rab5a Plasma membrane,
clathrin-coated vesicles
and early endosomes
Endocytosis, early endosome
fusion, nuclear signaling
through APPL
Hyperactivated in lung
adenocarcinoma;
upregulated in Alzheimer’s
Disease
Rab9a Late endosomes Transport from endosome to
TGN; lipid transport; lysosome
and lysosome-related
organelle biogenesis
Inhibited in Niemann–Pick C
disease
Rab11a, Rab11b
(neuron speciﬁc)
Golgi and recycling
endosomes, early
endosomes,
phagosomes
Trafﬁcking from the TGN to
apical recycling endosomes
and plasma membrane;
polarized trafﬁcking in
epithelia; phagocytosis in
macrophages
Upregulated in Barrett’s
epithelia;
neurodegeneration in
Huntington’s disease;
Schwann cell
demyelination in
Charcot-Marie-Tooth type
4C disease; implicated in
Batten disease
Rab14 Early endosome, Golgi Endocytic recycling of
transferrin; MHC class I
cross-presentation; TGN to
apical trafﬁcking in epithelia;
surfactant secretion in alveolar
cells; insulin-dependent
GLUT4 translocation
Rab15 Early/sorting endosome,
recycling endosome
Trafﬁcking through
sorting/recycling endosomes
to the plasma membrane
Rab17 Recycling endosome Epithelial transcytosis; polarized
trafﬁcking in kidney
Rab20 Phagosomes,
mitochondria,
endosomes
Vacuolar ATPase trafﬁcking in
kidney; HIF target in hypoxia
induced apoptosis;
phagosome acidiﬁcation and
maturation; Gap junction
biogenesis
Modulated by pathogens;
overexpressed in
pancreatic and breast
cancers
Rab21 Early endosomes;
macropinosomes
Endocytosis of integrins, cell
extracellular matrix adhesion
and motility; cytokinesis;
macropinocytosis
Cancer cell motility
Rab22a Early endosome, plasma
membrane
Transport of transferrin from
sorting endosomes to
recycling endosomes;
pathogen phagocytosis
Upregulated in hepatocellular
carcinoma; modulated by
mycobacterium
tuberculosis
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Table 1. Continued
Rab Localization Rab function Pathological condition
Rab25 Recycling endosome Apical recycling in epithelia,
microtubule dependent
transformation
Tumor progression and
cancer invasiveness
(breast and intestinal
cancers; ovarian cancer
and hepatocellular
carcinoma)
Rab31/Rab22b TGN and endosomes Mannose-6-phosphate
transport from TGN to
endosomes; transport of
myelination associated
proteins from TGN to
plasma membrane
Rab34 Golgi and endosomes Macropinosome formation,
phagosome maturation
and lysosome
morphogenesis
Diabetic nephropathy
Rab35 Endosomes and plasma
membrane
Fast endocytic recycling;
MHC class I and II
endocytosis and recycling;
Tcell receptor recycling;
phosphoinositide
regulation; neurite
outgrowth through
interfaces with Cdc42;
actin remodeling through
fascin effector
Pathogen phagocytosis and
trafﬁcking
Rab36 Golgi Late endosome and
lysosome clustering
Potential tumor suppressor
Rab39 Golgi and early
endosomes, AP1
membrane domains
Caspase-dependent-IL-1β
secretion and phagosomal
acidiﬁcation
Autophagy, phagocytosis and degradation
Rab7a Late endosomes and
lysosomes; stage I and
II melanosomes;
surfactant endocytosis
and signaling
Transport from early to late
endosomes and late
endosome to lysosome
fusion; bidirectional
transport of signaling
endosomes,
autophagosomes, and
multivesicular bodies on
microtubules in association
with dynein and kinesin
motor proteins. Axon
viability; phosphoinositide
homeostasis
Mutant in CMT2B; Helps in
pathogen entry and
survival; associated with
Niemann–Pick disease;
upregulated in Alzheimer’s
disease, thyroid cancer,
diffuse peritoneal malignant
mesothelioma and
adult-onset obesity
Rab24 Autophagosome nuclear
inclusions
Myelination; autophagosome
formation
Activated in cell culture
models of neuronal and
cardiomyocyte injury;
upregulated in
hepatocellular carcinoma
Rab32 Perinuclear vesicles,
mitochondria,
autophagic vesicles
Post-Golgi trafﬁcking of
melanogenic enzymes; ER
stress mediated apoptosis;
mitochondrial dynamics
Rab32 gene methylated in
inﬂammatory bowel
disease at transition to
invasive growth
CMT2B, Charcot-Marie-Tooth Disease Type 2B; TGN, trans-Golgi network.
aSource: Agola JO, Thesis.
bRab GTPases are clustered according to their functions in: (i) endocytosis and recycling; (ii) degradation, autophagy, phagocytosis
and pinocytosis.
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Fig. 2. Rab GTPases in endocytosis, recycling, and degradative pathways. Receptor mediated endocytosis occurs via clathrin-coated
vesicles and is regulated by Rab5 and Rab21. Internalized cargo is delivered to early/sorting endosomes. From here molecules
can return to the plasma membrane via fast or slow recycling routes through specialized recycling endosomes and the activities
of distinct Rab GTPases (further detailed in the text). Newly synthesized plasma membrane proteins are delivered from the trans-
Golgi network to recycling endosomes, while lysosomal hydrolases are delivered to early and late endosomes via two mannose
6-phosphate receptors. Recycling from early endosomes to the Golgi depends on Rab6, while Rab9 controls transport from the
late endosome to the trans-Golgi. Rab7 is a critical Rab GTPase on multiple degradative pathways; promoting late endosome,
phagosome and autophagosome fusion with lysosomes in cooperation with specialized Rab GTPases on each of these pathways.
In conjunction with Rac1, Rab7 is also pivotal in cadherin degradation by epithelia and neurons, as well as in bone resorption by
osteoclasts. Light green overlay encompasses endocytic and recycling circuits; light blue overlay encompasses degradative circuits;
and neutral overlay encompasses the biosynthetic/exocytic routes.
Each of the latter two pathways results in greater
EGFR at the plasma membrane in lieu of degrada-
tion. Rab5, Rab11, Rab21 and Rab25 are not only
important regulators of growth factor signaling and
downregulation, but also regulate cell adhesion and
motility through targeted insertion and recycling
of integrins (6). The selected examples empha-
size the importance of pathway integration in the
coordination of trafﬁcking, signaling, adhesion and
migration.
Besides regulating the fate of cell surface recep-
tors, early endosomes also serve as platforms for
the assembly of endosome-speciﬁc complexes crit-
ical to nuclear signaling and transcriptional reg-
ulation (18). For example, EGFR is sequestered
in Rab5 positive early endosomes together with
the Rab5 effector APPL1, promoting nuclear
translocation of APPL1 and changes in gene
expression (19). In neurons, retrograde transport
of the nerve growth factor signaling complexes via
endosomes is essential for axon viability through
Erk signaling and transcriptional regulation. This
pathway is negatively regulated by the Rab5 effec-
tor huntingtin, which increases endosome links to
the peripheral actin network and reduces nuclear
signaling (20). As illustrated, Rab-regulated traf-
ﬁcking and endosomal signaling is directly linked
to gene regulation.
Rab GTPase roles in degradation, autophagy,
phagocytosis and pinocytosis
Endocytosed and phagocytosed cargo destined
for degradation are transferred from early to
late endosomes and require fusion with lyso-
somes in a Rab7-dependent process (Fig. 2, blue
section) (21). Sequestration of cellular organelles
and cytoplasm in response to nutrient limitation is
regulated through autophagosome formation and
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a Rab7-regulated convergence with the endolyso-
somal system (22). Rab7 together with Rac1 is
involved in cell type speciﬁc functions including
the regulation of cell–cell adhesion through the
degradation of cadherins in epithelia and neurons
as well as osteoclast-mediated bone resorption reg-
ulating cell–cell adhesion (23). These examples
illustrate the complexity of the late endosomal
circuits.
Trafﬁcking and cargo sorting (including mem-
brane invagination and receptor sequestration) on
the early and late endocytic pathway require spa-
tially and temporally regulated phosphoinositide
synthesis and degradation, which are closely linked
to Rab5 and Rab7 GTPase activities (24, 25). The
activated GTPases in combination with PtdIns(3)
P-enriched domains enable binding of Rab GTPase
effectors bearing FYVE domains (Rab5 EEA1;
Rab7 FYCO) or PX domains (sorting nexins SNX)
and cargo recognition factors like retromer (26).
Lipid phosphatases serve to terminate the lipid-
signaling cascade. The endosomal lipid phos-
phatases MTM1 and MTMR2 responsible for
degrading PtdIns(3)P and PtdIns(3,5)P2 bind to
the hVps15/hVps34 lipid kinase causing the inac-
tivation of both kinase and phosphatase activi-
ties (27). The late endosomal PIKFyve (PIP5K3)
lipid kinase produces PtdIns(5)P/PtdIns(3,5)P2 and
associates with Rab9 via the p40 protein to
regulate late endosome to trans-Golgi transport
of the mannose 6-phosphate receptor (28). The
activity of PIKFyve is counterbalanced by the
FIG4 PtdIns(3,5)P2 5-phosphatase and thought to
be involved in melanosome and neurosecretory
granule formation (1). The cumulative data show
dynamic regulation of endosomal phosphoinositide
metabolism is central to Rab-mediated trafﬁcking.
Autophagy, phagocytosis, and pinocytosis are
specialized endocytic cellular processes regulated
by multiple Rab GTPases (Fig. 2). Phagocyto-
sis and pinocytosis are crucial for the uptake of
small particles and bacterial pathogens by cells
of the immune system, while autophagy is a
ubiquitous housekeeping function vital for the
autodigestion of cell constituents and pathogen
clearance (29). Overlapping GTPase subsets work
in concert to regulate phagosome (Rab14, Rab20,
Rab22a, b, Rab32, Rab34, Rab38, Rab39, Rab43),
macropinosome (Rab21, Rab34) and autophago-
some (Rab24, Rab32, Rab33) formation (30, 31).
For example, degradative enzyme delivery to
phagosomes and autophagosomes occurs through
a common mechanism involving fusion with
endo/lysosomes and is regulated by Rab7 (32).
Whether it is endocytosis, autophagy or phagocy-
tosis, the roles of Rab GTPase are tightly regulated
by interactions with partner proteins that ensure the
integrity of these vital processes.
Regulation of endocytic Rab GTPases
Principal processes pertinent to Rab regula-
tion include prenylation and membrane inser-
tion, nucleotide binding and hydrolysis, and effec-
tor protein interaction (Fig. 3) (4). Figure 3 also
shows points of therapeutic intervention that will
be discussed in a later section. Rab proteins are
initially synthesized as soluble proteins in the
cytosol (33), where they are recognized by the Rab
escort protein (REP) and presented to the Rab
geranylgeranyl transferase enzyme for the addi-
tion of one or two geranylgeranyl lipid groups
to C-terminal cysteine residues (34). Prenylation
together with the hypervariable C-terminus of the
Rab protein ensures stable and targeted membrane
insertion (35). On the target membrane, speciﬁc
GEFs convert Rab proteins from the GDP-bound
state into the GTP-bound state (36).
Active Rab GTPases interact temporally and
spatially with many effector molecules; includ-
ing sorting adaptors, tethering factors, kinases,
phosphatases and motor proteins that ensure
cargo sorting, vesicle transport and fusion (37).
Rab GTPase inactivation occurs through intrin-
sic GTPase hydrolysis and GAP-stimulated cataly-
sis (38). Recycling of the GDP-bound Rab GTPase
occurs through cytosolic recycling mediated by
guanine dissociation inhibitor (GDI). The whole
Rab GTPase regulatory process is conceptually
analogous to an electronic circuit system in which
GEFs taking Rabs to the active state can be viewed
as electronic signal ampliﬁers, while GAPs that
inactivate Rabs can be considered as signal atten-
uators. Effector molecules that couple Rab proteins
with downstream signaling events are analogous to
electronic signal integrators.
Alterations in endocytosis leading to disease
Numerous Rab GTPases on the endosomal and
autophagy circuits described in the previous
sections are implicated in acquired and genetic
diseases through up- or downregulation or mod-
ulation of their activities (Table 1). Such imbal-
anced increases or decreases in GTPase activity
and expression alter cell physiology, affect gene
expression and hence contribute to disease pathol-
ogy as we discuss further below.
Defects in rab regulatory factors lead to disease
by perturbing Rab GTPase membrane localiza-
tion or phosphoinositide metabolism and conse-
quently impinging on Rab activity. Choroideremia
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Fig. 3. Rab GTPase regulation and points of therapeutic intervention. The Rab GTPase activation cycle entails lipid modiﬁcation
through prenylation, nucleotide binding and hydrolysis regulated by guanine nucleotide exchange factors (GEFs) and GTPase
activating proteins (GAPs), effector protein interactions and cytosolic recycling by guanine dissociation inhibitor (GDI). Possible
modes of Rab GTPase inhibition include disruption of membrane association through prenylation inhibitors; GEF inhibitors to
block activation; nucleotide binding inhibitors to block activation analogous to kinase inhibitors; and protein–protein interaction
inhibitors.
(CHM) is an X-linked form of retinal degenera-
tion caused by loss of function mutants in REP-1
thereby reducing membrane association (39). Con-
versely, some patients diagnosed with X-linked
non-speciﬁc mental retardation have mutations
in the GDI1 gene that preclude proper Rab
recycling after vesicle fusion (40). Lipid kinases
and phosphatases central to rab-regulated trafﬁck-
ing are targets of disease-causing mutations in
humans (Lowes and Dents – OCRL1, corneal dys-
trophy – PIKFyve, ALS and Charcot-Marie-Tooth
disease – (CMT4J), neurologic and pigmentation
disorders – FIG4 and kidney disease – INPP5E,
OCRL1) (41–44).
Genetic mutations associated with Rab5 activa-
tion have been linked to pathogenesis of genetic
disorders like Ehlers-Danlos and the cutis laxa syn-
dromes (45). These connective tissue disorders are
caused by mutant Rab5-GEF RIN2 and are clini-
cally manifested by progressive facial coarsening,
gingival hypertrophy, severe scoliosis, sparse hair
and skin and joint hyperlaxity (45, 46). At the
molecular level, impaired Rab5-dependent trafﬁck-
ing results in decreased secretion of skin microﬁb-
rils and ﬁbulin-5 that are crucial for tissue elasticity
(46).
Amyotrophic lateral sclerosis 2, an autosomal
recessive form of motor neuron disease is associ-
ated with mutations in the ALS2 gene (47, 48).
ALS2/alsin is another Rab5 GEF important in
neuronal endocytosis and neurite outgrowth (49).
Mutations in ALS2 gene give rise to truncated
forms of alsin that increase glutamate receptor
degradation and alter autophagy (50). Altered
Rab5 GEF activities may affect Rab5–Rab7 con-
version. Support for Rab7 involvement is garnered
from the accumulation of enlarged APP/Rab7 pos-
itive vesicles in the mouse mutant wobbler (WR),
a model of sporadic amyotrophic lateral scle-
rosis (51). Thus, connective tissue and neuronal
degeneration caused by mutations in distinct Rab5
GEFs may affect both Rab5 and Rab7, as well as
downstream degradative pathways.
Neurodegenerative diseases and vision defects
may arise by impacting common effector pro-
teins (52). For example, inherited Huntington’s
disease is a devastating neurologic disease caused
by the expression of mutant Huntingtin (mHtt)
proteins with long polyglutamine tracts at their
N-termini. The altered proteins cause the accu-
mulation of abnormal intracellular aggregates and
inclusions. Clues regarding Htt function can be
surmised from studies of its interactions with
several exocytic and recycling Rab GTPases
(Fig. 4) (53–55). As illustrated, Htt is a critical
scaffolding protein. Normal Htt function promotes
Rab activation and motor protein assemblies that
drive vesicular transport on actin and microtubule
cytoskeletal networks, in part explaining how loss
of Htt function signiﬁcantly affects neuronal func-
tion. The Htt interacting protein, optineurin, causes
open angle glaucoma when mutant.
Genetic lipid storage disorders such as the neu-
rodegenerative Batten disease and Niemann–Pick
type C disease are caused by Rab GTPase inactiva-
tion by cholesterol accumulation due to impaired
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Fig. 4. Genetic diseases disrupt endocytic recycling circuits and cause neuronal degeneration, glaucoma and retinal degeneration.
The schematic depicts the normal functions and protein complexes of the Huntingtin (Htt) and optineurin (OPTN) proteins on
the Golgi and various endosomal compartments. Mutant Htt (mHtt) causes the severe neurodegenerative Huntington’s disease and
mutant OPTN causes vision disorders. (a) Htt protein is associated with the trans-Golgi and post-Golgi vesicles where it binds
OPTN, Fip2, Rab8 and myosin VI. mHtt expression causes OPTN and Rab8 dissociation and blocks lysosomal enzyme export to
endosomes. (b) Htt increases guanine nucleotide exchange factor (GEF)-mediated activation of Rab11a on recycling endosomes.
mHtt causes Rab11 inactivation and release from endosomes. (c) Htt binds HAP40 and Rab5 on early endosomes. mHtt causes early
endosome transfer from microtubules to actin ﬁlaments and peripheral immobilization. (d) Htt forms a complex with HAP1, the
p150dynein/dynactin motor complex that is important in trafﬁcking brain-derived neurotrophic factor (BDNF) containing vesicles
to late endosomes.
lysosomal hydrolase trafﬁcking (56, 57). Mutation
of the CLN3 gene, which encodes an endoso-
mal/lysosomal transmembrane protein, causes Bat-
ten disease (56). CLN3 protein forms a complex
with the microtubule binding protein Hook1/Btn2p
and several Rab GTPases (Rab7, Rab9 and
Rab11) (56). Ablation of CLN3 results in man-
nose 6-phosphate receptor accumulation in the
Golgi and reduction in maturation of lysosomal
enzymes (58). These data provide evidence that
positive beneﬁt may be provided in multiple lipid
storage diseases through increasing Rab7 and Rab9
protein expression and/or activity.
Rab25 is an illustrative example of altered
expression that is closely associated with multi-
ple solid tumor types; this includes ovarian, breast,
prostate and intestinal carcinomas (59). Rab25 is
an epithelial-speciﬁc GTPase operative on the
apical recycling circuit with Rab11a and important
in apical to basolateral transcytosis (60). Both
Rab25 and the two Rab11 isoforms share effectors
involved in cargo recognition and motor proteins
(FIP1-3, RIP11 and myosinVb) (61). In ovarian
cancer, Rab25 mRNA and protein expression are
signiﬁcantly upregulated due to gene ampliﬁcation
(1q22) and strongly correlated with cell invasion
and metastasis (Fig. 5) (62). Overexpressed Rab25
results in the transformation of normal intesti-
nal epithelia and depends on microtubule rear-
rangements, as well as microtubule modiﬁcations
that affect Rab25/MyoVb-dependent cargo recy-
cling (63). Rab25 and Rab11a are implicated in
EGFR and TGFβ signaling and trafﬁcking with
important impacts for the regulation of cell pro-
liferation and differentiation (64, 65).
The role of Rab25 in metastasis is based on
its interaction with integrin α5β1t op r o m o t e
regulated insertion at the tips of pseudopods,
312Endocytosis and small molecules
Fig. 5. Rab GTPase up- or downregulation can result in acquired disease. Rab25 serves as a well-studied example of how increased
or decreased GTPase expression can impact trafﬁcking of critical molecules involved in cell signaling and adhesion and adversely
affect cell physiology in cancer by increasing proliferation, dedifferentiation, motility and metastasis. It is speculated that in cases
where Rab25 expression is decreased (e.g. colon and some types of breast cancer) that additional mutations or factors may be
in play that are either synergistic with Rab25 underexpression or result in independence from proteins/functions regulated by the
Rab25 recycling route.
facilitating extracellular matrix adhesion and pen-
etration by invading tumor cells (66). Thus, imbal-
ances in Rab25-regulated processes can affect
normal epithelial function and lead to transforma-
tion. There, however, remains debate as to why
Rab25 is over expressed in some cancers and
absent in others. It is speculated that in early
stages of transformation Rab25 overexpression is
a universal driving factor as illustrated by over-
expression studies of Rab25 in intestinal epithe-
lia (Fig. 5). Subsequently, tumorigenesis in some
cases becomes independent of Rab25 function
either due to coordinated upregulation of other
recycling GTPases as is seen in hepatocellular car-
cinoma (Table 1) or due to additional alterations
in signaling pathways and receptors as suggested
by colon cancer animal model studies and dif-
ferences in breast cancer that are correlated with
grade (Fig. 5).
Alteration of Rab GTPase function through
direct mutation is best illustrated by Charcot-
Marie-Tooth type 2B (CMT2B) disease; a periph-
eral neuropathy with axonal degeneration linked
to four separate missense mutations in Rab7
gene (67, 68). The mutations target highly con-
served residues that reside on the surface of Rab7
and alter nucleotide exchange (68, 69). In neuronal
N2A and PC12 cell lines, mutant Rab7 expression
inhibits neurite outgrowth. Such changes in neu-
ronal differentiation are likely due to prolonged
phosphorylation of the TrkA receptor and altered
Erk nuclear signaling (68).
Similar to ALS2, CMT2B mutant proteins may
alter Rab5–Rab7 conversion, Rab7–effector pro-
tein interactions and impact the Rab7-regulated
trafﬁcking required for maintenance of axon via-
bility (Fig. 6). For example, the CORVET and
HOPS protein complexes identiﬁed in yeast and
conserved in mammalian systems are thought
to enable transition of cargo from early to
late endosomes and lysosomes and facilitate a
Rab5–Rab7 hand-off (Fig. 6, inset) (26). GTP-
bound Rab7 recruits the dynein/dynactin motor
complex through the Rab interacting lysoso-
mal protein (RILP) and in conjunction with
Rabring7 promotes growth factor degradation (70,
71). Further work is, however, needed to deter-
mine precisely how the Rab7 CMT2B mutants may
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Fig. 6. Axon viability depends on coordinated endocytic trafﬁcking and signaling. Nerve growth factor (NGF) binds to the TrkA
receptor tyrosine kinase and stimulates phosphorylation and internalization. Endocytosed TrkA is transported from Rab5-positive
early endosomes to Rab7-positive late endosomes. In peripheral neurons long distance transport of late endosomes to the cell body is
critical for growth factor degradation and proper nuclear signaling to maintain cell viability and differentiation. Transport occurs on
microtubules through Rab7, the Rab interacting lysosomal protein (RILP) effector and dynactin minus-end directed motor complex.
Return transport to the synapse is mediated by Rab7 in conjunction with a plus-end directed kinesin motor, likely KIF3a. Inset
illustrates endosomal membrane protein complexes involved in Rab conversion that allows transfer of cargo along the degradative
pathway. Several conserved multimeric protein complexes ﬁrst identiﬁed in yeast are thought to aid in Rab conversion, directed
transport and fusion (RETROMER endosome to Golgi; CORVET early to late endosome; HOPS late endosome to lysosome).
impact effector and regulatory protein interactions
to fully understand the cause of disease pathology.
The given examples underscore the importance
of proper Rab regulation for maintaining normal
cell physiology. Notably, changes in localization,
increased or decreased activity, up- or downregu-
lation can all contribute to disease. The exquisite
tissue speciﬁcity of diseases that involve ubiqui-
tously expressed proteins remains to be further
explored, but suggests that targeted therapeutics
could be a useful strategy.
Endocytic Rab GTPases: therapeutic targets
and precedents
Prospects for therapeutic intervention relevant to
the described diseases have in many cases been
reviewed separately. Here we focus primarily
on interventions that target the Rab GTPases
through modulation of membrane association,
nucleotide binding or exchange, and inhibition of
protein–protein interactions (Fig. 3) and include
some limited description of interventions directed
toward pathway interventions.
One strategy for inhibiting small GTPase func-
tion is to block membrane recruitment, through
inhibition of protein prenylation (72). A limitation
of this approach is the broad cellular importance
of lipid modiﬁcations for the proper functioning
of many GTPase families among other proteins
and overlapping activity of prenylation inhibitors
against farnesyl and geranylgeranyl transferases.
Altering membrane recruitment of Rab GTPases
has, however, shown particular selectivity and
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beneﬁt in the area of bone metabolism. Examples
here include NE10790 (a nitrogen-containing
bisphosphonate) and zoledronic acid (73, 74).
NE10790 was identiﬁed as a farnesyl diphos-
phate synthase inhibitor speciﬁc for osteoclasts and
macrophages that blocked bone resorption and far-
nesylation of numerous small GTPases including
Rab6 (73). The statin family of drugs that act by
inhibiting the biosynthesis of isoprenoids has also
been shown to have some efﬁcacy against Rab
GTPases (75). For example, mevastatin, which
acts as non-speciﬁc reversible inhibitor of HMG-
CoA reductase, blocked Rab5a targeting to trans-
ferrin receptor-positive early endosomes in HeLa
cells (76). Statin use has, however, been linked
to myopathy and rhabdomyolysis and thus, the
quest for more speciﬁc prenylation inhibitors is
actively moving forward (77). Even if not speciﬁc,
the prenylation inhibitor results suggest that the
strategy of delocalizing GTPases from membranes
can be effective in some cases.
Another approach for modulating activation is
through the inhibition of regulatory protein inter-
actions. As proof-of-principle, the fungal metabo-
lite brefeldin A has been successfully used as
an inhibitor of ADP-ribosylation factor 1 (Arf1)
GTPase (78, 79). Brefeldin A functions by tar-
geting speciﬁc guanine GEFs, including Golgi
complex-speciﬁc Brefeldin A resistance factor 1
(GBF1). A stable complex of Brefeldin A-GDP-
Arf1-GEF on membranes prevents GDP/GTP
exchange of Arf1 on membrane surfaces and dis-
rupts Golgi morphology (80). Other Arf GTPase
targeting molecules that may provide a platform
for generating similar inhibitors for Rab GTPase
GEFs are Exo2 and LG186 (81).
Among the Rho-family of GTPases, GEF
inhibitors have been identiﬁed through screening
and rational drug design, leading to a handful
of Rho-family selective inhibitors (82). Thus far,
there are no similar inhibitors of Rab GEFs. The
growing list of known, speciﬁc Rab GEFs and
GAPs together with growing structural informa-
tion makes the targeting of Rab regulatory pro-
teins through inhibitors or activators a tractable
and worthy strategy. The therapeutic success and
selectivity of competitive adenine nucleotide bind-
ing inhibitors for targeting tyrosine kinases and
similar compounds for GTPases prompted our
group to undertake a systematic screen for gua-
nine nucleotide binding inhibitors. Using puriﬁed
proteins immobilized on beads and assaying ﬂuo-
rescent GTP binding by ﬂow cytometry we identi-
ﬁed inhibitors selectively for Rho or Rab family
GTPase members (83) (Agola et al., submitted).
The versatility of ﬂow cytometry measurements
enabled the identiﬁcation of a separate class of
GTPase activators in the same screen (84). Acti-
vators might be useful for diseases where wild-
type GTPase expression is reduced or there is
altered activity, such as Niemann–Pick type C dis-
ease, Huntington’s disease, Charcot-Marie-Tooth
disease, and some cancers. Inhibitors of guanine
nucleotide binding would be expected to block
activation in cells, and with reﬁnement to make
them GTPase speciﬁc could offer unprecedented
opportunities for modulating individual pathways
in diseases where overexpression and hyperacti-
vation of GTPases are a problem, e.g. cancers,
neurodegenerative diseases, infectious diseases.
In some cases, targeting of associated signal-
ing pathways rather than directly targeting the
small GTPase may be beneﬁcial. For example,
valproic acid has been used to impact pathways
linked to Rab5- and Rab7-regulated functions. Val-
proic acid is therapeutically used as a mood sta-
bilizer for the treatment of bipolar disorder (85).
Valproic acid is a histone deacetylase inhibitor
that promotes neuronal differentiation and mod-
ulates signal-regulated kinase (ERK) and glyco-
gen synthase kinase3β (GSK3β) pathways (86).
In dorsal root ganglion neurons expressing a
CMT2B-associated mutant Rab7, valproic acid
was found to improve neurite formation via the
c-Jun N-terminal kinase (87). Even though val-
proic acid does not target the GTPases directly,
it is beneﬁcial in CMT2B disease by altering gene
expression and signaling.
Niemann–Pick type C disease is marked by
the accumulation of unesteriﬁed cholesterol within
the lysosomal storage organelles and inhibition of
multiple Rab GTPases. Recently,2-hydroxypropyl-
β-cyclodextrin gained approval for treatment of
Niemann–Pick type C disease (88). In human
NPC1 and NPC2 mutant ﬁbroblasts, treatment
with 2-hydroxypropyl-β-cyclodextrin was reported
to signiﬁcantly reduce cholesterol levels in the
storage organelles and relieve Rab GTPase inhi-
bition (89). The systemic effects of cholesterol
depletion are minimized during treatment of Nie-
mann–Pick type C disease through cerebrospinal
administration. On the contrary, protein aggrega-
tion underlying neurodegeneration is worsened by
2-hydroxypropyl-β-cyclodextrin derivatives, which
would suggest caution in the use of β-cyclodextrin
analogs to correct cholesterol homeostasis (90).
Summary
The elucidation of the Rab GTPase circuitry that
regulates endocytic membrane trafﬁcking is pro-
ceeding at a rapid rate with a large literature that
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we have summarized in this review. Based on the
highlighted studies, key themes emerge. Firstly,
Rab GTPases function as scaffolds for the temporal
and spatial regulation of cargo transport. Secondly,
Rab GTPase functions are coordinately regulated
through cascades that involve shared effectors and
regulatory proteins and are responsive to cellular
demand. Thirdly, Rab GTPase pathways interface
hierarchically with other GTPases to integrate cell
signaling and trafﬁcking. Greater understanding of
Rab GTPase functions has been gained through
a combination of basic science and disease-based
studies. Fourthly, dysregulated or mutant Rab
GTPases and accessory proteins underlie many
acquired and genetic human disease and is based
on the many important functions Rab GTPases
have in cellular and physiologic homeostasis.
Foundational studies show that GTPases can be
targeted by altering nucleotide binding or regu-
latory protein interactions with small molecules.
Questions remain as to how tissue-speciﬁc patholo-
gies arise from mutant GTPases that are ubiquitous
and expressed in all cells. This may be due to
redundant pathways or GTPase functions in some
cell types, as well as tissue-speciﬁc effectors or
regulators. As we move toward GTPase-targeted
interventions and therapeutics, greater clarity in
this arena will be essential. It will also be important
to couple GTPase interventions with appropriate
tissue-targeting strategies.
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